- 2024,11,05
Listing services for enterprises on the Shanghai Stock Exchange
Company Introduction
Zhejiang Chengyi Pharmaceutical Co., Ltd. is specialized in the R&D, production and sales of preparations and APIs. Its products cover arthritis, diuresis, sedation and brain tonic, anti-virus and anti-tumor, etc. Its main products include Glucosamine hydrochloride APIs and preparations, tolasemide injection and capsules, Gastrodin APIs, Ribavirin and Azathioprine APIs, etc. Among them, Glucosamine hydrochloride APIs and preparations, tolasemide preparations and Gastrodin APIs mainly focus on the domestic market, and Ribavirin and Azathioprine APIs are mainly exported.
At present, the company and its subsidiaries have 65 drug production approval numbers. Among them, 43 drug regulations were listed in the national medical insurance catalogue (including 31 Class A and 12 Class B drug regulations), 15 drugs were listed in the National Essential medicines Catalogue (2012), and 31 product regulations were produced throughout the year. Has 4 national new drug varieties, including 3 Class II new drugs and 1 Class IV new drug; Has 9 invention patents and 3 utility model patents.
In the future, the company will adhere to the policy of "quality first, user first", with innovation as the driving force, talent as the foundation, and market orientation. We will adhere to both internal and external development, accelerate product upgrading and upgrading, promote the transformation of product structure from raw materials to formulations, and lead the transformation of products to marine products; Build the company into a drug production base led by marine pharmaceuticals, biopharmaceuticals, and traditional Chinese medicine.
Issuance Overview
